1. Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer
- Author
-
Markus Joerger, B Klaeser, J.T Kluckert, Silke Gillessen, T Warzinek, and Hans-Peter Schmid
- Subjects
Male ,medicine.medical_specialty ,Paclitaxel ,Urology ,Penile Neoplasm ,Bleomycin ,Carboplatin ,chemistry.chemical_compound ,Fluorodeoxyglucose F18 ,Antineoplastic Combined Chemotherapy Protocols ,Carcinoma ,medicine ,Humans ,Penile cancer ,Penile Neoplasms ,Cisplatin ,medicine.diagnostic_test ,business.industry ,Remission Induction ,Middle Aged ,medicine.disease ,Antineoplastic Agents, Phytogenic ,Combined Modality Therapy ,Survival Analysis ,Surgery ,chemistry ,Positron emission tomography ,Lymphatic Metastasis ,Carcinoma, Squamous Cell ,Lymph Node Excision ,Lymph Nodes ,Radiology ,business ,Penis ,Tomography, Emission-Computed ,medicine.drug - Abstract
Penile cancer is rare in Western countries. High-risk patients are considered for prophylactic inguinal lymphadenectomy. For advanced disease, a triplet drug regimen consisting of bleomycin, methotrexate, and cisplatin is the most active combination tested so far. A 62-year-old man with penile cancer underwent partial penile amputation but presented 10 months later with inguinal nodal metastasis. He received three cycles of paclitaxel/carboplatin with marked clinical and radiologic (computed tomography and positron emission tomography) tumor regression. Later, complete resection of the inguinal nodal metastasis was performed. The paclitaxel/carboplatin combination has potential activity in penile cancer. Positron emission tomography may be used for screening of nodal metastases.
- Published
- 2004
- Full Text
- View/download PDF